

# Leslie Stewart Massad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1670692/publications.pdf>

Version: 2024-02-01

89  
papers

4,981  
citations

159585  
30  
h-index

91884  
69  
g-index

89  
all docs

89  
docs citations

89  
times ranked

5207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.	0.8	28
2	Trends in Bacterial Vaginosis Prevalence in a Cohort of U.S. Women with and at Risk for HIV. <i>Journal of Women's Health</i> , 2022, 31, 726-732.	3.3	2
3	The Association Between HIV Status, Estradiol, and Sex Hormone Binding Globulin Among Premenopausal Women in the Women's Interagency HIV Study. <i>Journal of Women's Health</i> , 2022, 31, 183-193.	3.3	4
4	Impacts of the COVID-19 pandemic on cervical cancer will be severe. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1140-1140.	2.3	4
5	Cervical cancer risk and screening among women seeking assistance with basic needs. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 368.e1-368.e8.	1.3	10
6	Addressing Unmet Basic Needs to Improve Colposcopy Adherence Among Women With Abnormal Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 106-112.	1.9	6
7	Frequency of high-grade squamous cervical lesions among women over age 65 years living with HIV. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 411.e1-411.e7.	1.3	0
8	Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.	1.4	6
9	Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study. <i>International Journal of Cancer</i> , 2020, 146, 3320-3328.	5.1	9
10	Longitudinal assessment of abnormal Papanicolaou test rates among women with HIV. <i>Aids</i> , 2020, 34, 73-80.	2.2	4
11	A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213.	1.4	3
12	Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 337-342.	1.9	12
13	Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.	2.5	10
14	Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292.	1.4	11
15	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
16	Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110.	0.6	6
17	Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6-year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92.	1.4	10
18	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57

#	ARTICLE	IF	CITATIONS
19	Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140.	0.6	6
20	Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 1-5.	0.6	4
21	What Role Should Cytology Play in Cervical Cancer Screening?. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 205-209.	1.9	3
22	Anticipating the Impact of Human Papillomavirus Vaccination on US Cervical Cancer Prevention Strategies. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 123-125.	1.9	1
23	A prospective study of risk-based colposcopy demonstrates improved detection of cervical precancers. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 604.e1-604.e8.	1.3	23
24	Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 83-89.	1.6	8
25	Natural History of Cervical Intraepithelial Neoplasia-2 in HIV-Positive Women of Reproductive Age. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 573-579.	2.1	3
26	Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer. <i>Aids</i> , 2018, 32, 2821-2826.	2.2	14
27	Prolonged Amenorrhea and Resumption of Menses in Women with HIV. <i>Journal of Women's Health</i> , 2018, 27, 1441-1448.	3.3	17
28	In Defense of a Simplified, Practical Colposcopic Terminology. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 233-234.	1.9	0
29	Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits. <i>Gynecologic Oncology Reports</i> , 2017, 22, 48-51.	0.6	6
30	Cervical cancer incidence after up to 20 years of observation among women with HIV. <i>International Journal of Cancer</i> , 2017, 141, 1561-1565.	5.1	16
31	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 192-193.	1.3	0
32	Correlates of Bacterial Vaginosis Over Long-Term Follow-Up: Impact of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 432-439.	1.1	6
33	The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women. <i>Journal of Infectious Diseases</i> , 2016, 214, 1361-1369.	4.0	51
34	Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 766.e1-766.e9.	1.3	23
35	Multitype Infections With Human Papillomavirus: Impact of Human Immunodeficiency Virus Coinfection. <i>Sexually Transmitted Diseases</i> , 2016, 43, 637-641.	1.7	9
36	Clinical Outcomes among Women with Mucinous Adenocarcinoma of the Ovary. <i>Gynecologic and Obstetric Investigation</i> , 2016, 81, 411-415.	1.6	10

#	ARTICLE	IF	CITATIONS
37	A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. <i>Gynecologic Oncology</i> , 2016, 141, 364-370.	1.4	21
38	Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 354.e1-354.e6.	1.3	39
39	Self-reported human papillomavirus vaccination does not have an impact on the risk for high-grade cervical intraepithelial neoplasia among women referred for colposcopy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 123-126.	1.3	1
40	Selecting Patients for Endocervical Curettage. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 271-272.	1.9	9
41	Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44.	0.6	3
42	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. <i>Gynecologic Oncology</i> , 2015, 136, 178-182.	1.4	374
43	Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. <i>Clinical Infectious Diseases</i> , 2015, 61, 1573-1581.	5.8	34
44	Incidence of cervical precancers among HIV-seropositive women. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 606.e1-606.e8.	1.3	61
45	Changes in knowledge of cervical cancer following introduction of human papillomavirus vaccine among women at high risk for cervical cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 37-40.	0.6	9
46	Long-term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse after abnormal cytology: Impact of HIV infection. <i>International Journal of Cancer</i> , 2014, 134, 1854-1861.	5.1	6
47	Accuracy of colposcopy in HIV seropositive and seronegative women with abnormal Pap tests. <i>Gynecologic Oncology</i> , 2014, 135, 481-486.	1.4	2
48	Long-term cumulative detection of human papillomavirus among HIV seropositive women. <i>Aids</i> , 2014, 28, 2601-2608.	2.2	47
49	Developing Guidelines for Cervical Cancer Prevention in the Face of Diagnostic Complexity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 349-353.	4.9	5
50	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S1-S27.	1.9	614
51	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Obstetrics and Gynecology</i> , 2013, 121, 829-846.	2.4	617
52	Correlating Knowledge of Cervical Cancer Prevention and Human Papillomavirus With Compliance After Colposcopy Referral. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 98-105.	1.9	6
53	Effect of Human Immunodeficiency Virus Infection on the Prevalence and Incidence of Vaginal Intraepithelial Neoplasia. <i>Obstetrics and Gynecology</i> , 2012, 119, 582-589.	2.4	18
54	Negative Predictive Value of Pap Testing. <i>Obstetrics and Gynecology</i> , 2012, 120, 791-797.	2.4	17

#	ARTICLE	IF	CITATIONS
55	Trends in Contraceptive Use Among Women With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2012, 120, 783-790.	2.4	38
56	Cervicovaginal human papillomavirus (HPV) infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. <i>International Journal of Cancer</i> , 2012, 131, 1472-1478.	5.1	14
57	Effect of Stress and Depression on the Frequency of Squamous Intraepithelial Lesions. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 42-47.	1.9	9
58	Genital Warts and Vulvar Intraepithelial Neoplasia. <i>Obstetrics and Gynecology</i> , 2011, 118, 831-839.	2.4	43
59	Knowledge of cervical cancer prevention and human papillomavirus among women with HIV. <i>Gynecologic Oncology</i> , 2010, 117, 70-76.	1.4	25
60	Marginal and Mixed-Effects Models in the Analysis of Human Papillomavirus Natural History Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 159-169.	2.5	82
61	Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women. <i>Journal of Infectious Diseases</i> , 2010, 201, 681-690.	4.0	132
62	The impact of human papillomavirus vaccination on cervical cancer prevention efforts. <i>Gynecologic Oncology</i> , 2009, 114, 360-364.	1.4	36
63	The value of perioperative imaging in patients with uterine sarcomas. <i>Gynecologic Oncology</i> , 2009, 115, 37-40.	1.4	9
64	Discussion: "Biomarkers for detection of early ovarian cancer"™ by Nosov et al. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, e1-e3.	1.3	604
65	Long-term incidence of cervical cancer in women with human immunodeficiency virus. <i>Cancer</i> , 2009, 115, 524-530.	4.1	58
66	The Accuracy of Colposcopic Grading for Detection of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 137-144.	1.9	119
67	Histologic Correlates of Glandular Abnormalities in Cervical Cytology Among Women With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2009, 114, 1063-1068.	2.4	8
68	Squamous Cervical Lesions in Women With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2008, 111, 1388-1393.	2.4	57
69	High-Grade Cervical Disease in Adolescents With HIV. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 199-203.	1.9	5
70	Assessing New Technologies for Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 311-315.	1.9	10
71	Interobserver Agreement in the Assessment of Components of Colposcopic Grading. <i>Obstetrics and Gynecology</i> , 2008, 111, 1279-1284.	2.4	68
72	Outcomes After Diagnosis of Vaginal Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 16-19.	1.9	31

#	ARTICLE	IF	CITATIONS
73	Hysterectomy Among Women With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 44, 566-568.	2.1	7
74	Outcomes After Treatment of Cervical Intraepithelial Neoplasia Among Women With HIV. <i>Journal of Lower Genital Tract Disease</i> , 2007, 11, 90-97.	1.9	58
75	Contraceptive Use among U.S. women with HIV. <i>Journal of Women's Health</i> , 2007, 16, 657-666.	3.3	47
76	Home Study Course: Winter 2006. <i>Journal of Lower Genital Tract Disease</i> , 2006, 10, 66-68.	1.9	0
77	Knowledge of the Cervical Cancer Screening Process Among Rural and Urban Illinois Women Undergoing Colposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2006, 10, 252-255.	1.9	20
78	Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women. <i>Journal of Women's Health</i> , 2006, 15, 591-598.	3.3	36
79	Outcome After Negative Colposcopy Among Human Immunodeficiency Virus-Infected Women With Borderline Cytologic Abnormalities. <i>Obstetrics and Gynecology</i> , 2005, 106, 525-532.	2.4	16
80	Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus-Positive Women. <i>Journal of the National Cancer Institute</i> , 2005, 97, 577-586.	6.3	558
81	Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. <i>Journal of General Virology</i> , 2005, 86, 2709-2720.	2.9	47
82	Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. <i>Aids</i> , 2004, 18, 109-113.	2.2	54
83	Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1241-1248.	1.3	60
84	Natural History of Grade 1 Cervical Intraepithelial Neoplasia in Women With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2004, 104, 1077-1085.	2.4	31
85	Using Patient History to Predict High-Grade Cervical Dysplasia and Cancer in Women with Borderline Cervical Cytologic Results. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 207-211.	1.9	2
86	Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1062-1071.	6.3	204
87	Improving Compliance with Cervical Cancer Prevention Programs. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 95-100.	1.9	1
88	Guidelines for Cervical Cancer Screening From the American Cancer Society: The Earth Is Moving. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 87-88.	1.9	5
89	The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. <i>Aids</i> , 2001, 15, 2157-2164.	2.2	165